Given the severity of the HCV epidemic, in the late 1990s the Egyptian government encouraged international collaborations to strengthen the local research infrastructure for HCV treatment and control.

French teams, with the support of the Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) and the European Commission (EC), liaised with universities in Cairo and gradually built a network that led to the creation of the ANRS research site on viral hepatitis in 2007.

This network, coordinated by Prof Gamal Esmat (National Hepatology and Tropical Medicine Research Institute, Cairo) and Prof Arnaud Fontanet (Institut Pasteur, Paris), brings together the Egyptian Ministry of Health and Population (MOHP), the National Hepatology and Tropical Medicine Research Institute (NHTMRI, Cairo), Universities like Ain Shams, Cairo, Minia and Mansoura, and, in France, the Institut Pasteur, the Inserm, and several teaching hospitals. Funding is provided through the Egyptian MOHP and the French Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS), with research grants from the Egyptian Science and Technology Development Fund (STDF), the ANRS, the European Commission, and the Wellcome Trust.


Introduction of Sofosbuvir in Egypt

In July 2014, Gilead and the Egyptian government signed an agreement for a treatment expansion of Sovaldi® (Sofosbuvir). Read more

Scientific Advisory Board Meeting

The Scientific Advisory Board Meeting was held in Paris February 15-16, 2013.

Read more

fp7_01fp7_02 This project is funded
by the European Union